Selected publications:
Markaki I, Ntetsika T, Sorjonen K, Svenningsson P; BioPark Study Group. Euglycemia Indicates Favorable Motor Outcome in Parkinson’s Disease. Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28545.
Mantas I, Vallianatou T, Yang Y, Shariatgorji M, Kalomoiri M, Fridjonsdottir E, Millan MJ, Zhang X, Andrén PE, Svenningsson P. TAAR1 dependent and independent actions of tyramine in interaction with glutamate underlie central effects of monoamine oxidase inhibition. Biological Psychiatry (2020). https://doi.org/10.1016/j.biopsych.2020.12.008.
Sousa VC, Mantas I, Stroth N, Hager T, Pereira M, Jiang H, Jabre S, Paslawski W, Stiedl O, Svenningsson P. P11 deficiency increases stress reactivity along with HPA axis and autonomic hyperresponsiveness. Mol Psychiatry (2020). https://doi.org/10.1038/s41380-020-00887-0
Laffita-Mesa JM, Nennesmo I, Paucar M, Svenningsson P. A Novel Duplication in ATXN2 as Modifier for Spinocerebellar Ataxia 3 (SCA3) and C9ORF72-ALS. Mov Disord. 2021 Feb;36(2):508-514. doi: 10.1002/mds.28334.
Svenningsson P, Odin P, Dizdar N, Johansson A, Grigoriou S, Tsitsi P, Wictorin K, Bergquist F, Nyholm D, Rinne J, Hansson F, Sonesson C, Tedroff J; IRL752 Collaborators. A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson’s Disease Dementia. Mov Disord. (2020) Jun;35(6):1046-1054.
Paslawski W, Zareba-Paslawska J, Zhang X, Hölzl K, Wadensten H, Shariatgorji M, Janelidze S, Hansson O, Forsgren L, Andrén PE, Svenningsson P. α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson’s disease patients. Proc Natl Acad Sci U S A. (2019) Jul 23;116(30):15226-15235
Green H, Zhang X, Tiklova K, Volakakis N, Brodin L, Berg L, Greengard P, Perlmann T, Svenningsson P. Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson’s disease. Proc Natl Acad Sci U S A. (2017) Mar 7;114(10):2735-2740
Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study. Brain. (2015) Apr;138(Pt 4):963-73.
Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois JM, Nomikos GG, Greengard P. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science. (2006) Jan 6;311(5757):77-80.
Full publications: